Commerce Resources Corp. (TSXV:CCE)

ASLAN Pharmaceuticals Cash Flow Statement

Financials in millions CAD. Fiscal year is November - October.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr 30, 2025	Oct 31, 2024	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021	Oct 31, 2020
Net Income	-30.23	-28.7	-1.7	-0.72	-0.45	-0.83
Depreciation & Amortization	0.03	0.03	0.03	0.02	-	-
Loss (Gain) From Sale of Assets	28.52	28.52	-	-	-	-
Loss (Gain) From Sale of Investments	0	0	0	0.02	-0.01	-0
Loss (Gain) on Equity Investments	0.22	0.1	-	-	-	-
Stock-Based Compensation	0.11	-	0.35	0.3	0.37	0.02
Other Operating Activities	-1.67	-1.61	0.36	-0.57	-0.95	-
Change in Accounts Payable	0.44	0.09	-0.04	0.05	-0.24	-0.06
Change in Income Taxes	-0.04	-0.57	0.22	-0.26	-0.27	0.13
Change in Other Net Operating Assets	0.31	-0.18	0.26	0.39	-0.81	-0.09
Operating Cash Flow	-2.31	-2.32	-0.51	-0.77	-2.36	-0.83
Capital Expenditures	-5.87	-5.87	-2.48	-4.31	-3.31	-0.42
Investment in Securities	-	-	-	0	-	0.41
Investing Cash Flow	-6.2	-5.87	-2.48	-4.31	-3.31	-0.01
Long-Term Debt Repaid	-	-0.04	-0.04	-0.03	-	-
Net Debt Issued (Repaid)	-0.04	-0.04	-0.04	-0.03	-	-
Issuance of Common Stock	7.06	7.06	6.76	2.51	8.12	1.74
Other Financing Activities	-0.29	-0.29	-0.29	-0.15	-0.24	-0.09
Financing Cash Flow	6.72	6.72	6.43	2.34	7.88	1.65
Net Cash Flow	-1.8	-1.47	3.44	-2.75	2.21	0.81
Free Cash Flow	-8.18	-8.19	-2.99	-5.08	-5.67	-1.25
Free Cash Flow Per Share	-0.04	-0.04	-0.03	-0.06	-0.08	-0.03
Levered Free Cash Flow	-5.4	-6.54	-3.32	-4.16	-4.96	-0.78
Unlevered Free Cash Flow	-5.39	-6.53	-3.31	-4.15	-4.96	-0.78

Updated Mar 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.